Angstrom Pharmaceuticals, Inc. release
Angstrom Pharmaceuticals, Inc.
26.10.2011 16:59
---------------------------------------------------------------------------
Angstrom Pharmaceuticals Announces Publication of the Discovery of the Cellular
Target of Its A6 Phase II Clinical Compound Resulting From Its Joint Study With
Apricus Biosciences
Preclinical Results Elucidate the Mechanism of Action of A6 Peptide in Blocking
Cancer Cell Migration
SAN DIEGO, 2011-10-26 16:42 CEST (GLOBE NEWSWIRE) -- Angstrom Pharmaceuticals,
Inc. ('Angstrom' or the 'Company') announced today that the Molecular Cancer
Therapeutic Journal, a peer reviewed journal, has published results elucidating
the cellular target of its A6 phase II compound. The collaborative effort
between Apricus Biosciences, Inc. (Nasdaq:APRI) ('Apricus Bio') and Angstrom
resulted in the discovery of the mechanism of action by which Angstrom's A6
peptide blocks the migration of CD44-expressing cancer cells. Angstrom
previously reported that results from a pharmacokinetic pre-clinical study
showed significant improvement in the delivery and half life of A6, a
proprietary peptide treatment for ovarian cancer that was in Phase II
development by Angstrom. Specifically, the Company reported at that time that
the incorporation of Apricus Bio's NexACT(r) technology enabled the dose of A6 to
be cut by half, or from twice per day to once per day delivered subcutaneously,
while achieving the same level of efficacy in the mouse lung metastasis model.
Dr. Malcolm Finlayson, President and Chief Executive Officer of Angstrom,
commented, 'This study elucidates the mechanism of action and the cellular
target of the A6 peptides in blocking cancer cell migration and we believe,
when examined with the previous pre-clinical results we published in 2010 with
Apricus Bio, demonstrate that their proprietary NexACT(r) technology can play an
important role in the subcutaneous delivery of peptide drugs. We look forward
to continuing to work with Apricus Bio to develop a product or products in the
peptide field that can take advantage of NexACT(r)'s apparently positive effect
in this area.'
The abstract to the study is available and can be accessed at the following
site:
mct.aacrjournals.org/content/early/2011/08/31/1535-7163.MCT-11-0351.abstract.
About Angstrom's A6 Peptide Technology
A6 is in clinical development for ovarian cancer and in preclinical development
for the treatment of diabetic retinopathy and age-related macular degeneration.
A6 binds to the cell surface receptor CD44 and inhibits cancer cell migration.
The IC50 for A6 inhibition of chemotaxis in several human cancer cell lines is
in the nM-pM range indicating a physiologically relevant mechanism. Furthermore
the inhibition of cancer cell migration persists for 18-20 hours following the
removal of A6. A6 is stable in phosphate buffer for more than 5 years when
stored 2-8*C. A6 has been shown to have no dose-limiting toxicity in animal
studies and consistently demonstrates an excellent safety profile across animal
studies and human trials. The Company has recently completed a
placebo-controlled Phase 2 clinical trial evaluating A6 in women with
biochemical recurrent ovarian cancer. In this study, the time to tumor
progression was doubled in patients receiving A6 over that of placebo control
(p<0.01). A second Phase 2 clinical trial in patients with persistent or
recurrent ovarian cancer is in progress. This trial is being conducted by the
Gynecological Oncology Group (NCI) and the translational research component of
this study will assess CD44 as a biomarker
About Angstrom Pharmaceuticals
Angstrom Pharmaceuticals, Inc., a privately held pharmaceutical company
headquartered in San Diego, California, is developing a new class of
proprietary drugs that treat diseases involving cell migration, invasion, and
metastasis. Angstrom's lead product, A6 peptide, is a First-in-Class
'Oncoparalytic', stopping tumors from metastasizing by paralyzing cancer cells.
For further information, go to www.angstrominc.com/
Angstrom Pharmaceuticals' Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with
the exception of the historical information contained in this release, the
matters described herein contain forward-looking statements that involve risks
and uncertainties that may individually or mutually impact the matters herein
described for a variety of reasons that are outside the control of the Company.
Readers are cautioned not to place undue reliance on these forward-looking
statements as actual results could differ materially from the forward-looking
statements contained herein.
CONTACT: Angstrom Pharmaceuticals, Inc.
Dr. Malcolm Finlayson
Chief Executive Officer
990 Highland Drive, Suite 314
Solana Beach, CA 92075
Telephone: (858) 314-2356
Fax: (858) 314-2355
News Source: NASDAQ OMX
26.10.2011 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Angstrom Pharmaceuticals, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901789803
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Angstrom Pharmaceuticals, Inc.
26.10.2011 16:59
---------------------------------------------------------------------------
Angstrom Pharmaceuticals Announces Publication of the Discovery of the Cellular
Target of Its A6 Phase II Clinical Compound Resulting From Its Joint Study With
Apricus Biosciences
Preclinical Results Elucidate the Mechanism of Action of A6 Peptide in Blocking
Cancer Cell Migration
SAN DIEGO, 2011-10-26 16:42 CEST (GLOBE NEWSWIRE) -- Angstrom Pharmaceuticals,
Inc. ('Angstrom' or the 'Company') announced today that the Molecular Cancer
Therapeutic Journal, a peer reviewed journal, has published results elucidating
the cellular target of its A6 phase II compound. The collaborative effort
between Apricus Biosciences, Inc. (Nasdaq:APRI) ('Apricus Bio') and Angstrom
resulted in the discovery of the mechanism of action by which Angstrom's A6
peptide blocks the migration of CD44-expressing cancer cells. Angstrom
previously reported that results from a pharmacokinetic pre-clinical study
showed significant improvement in the delivery and half life of A6, a
proprietary peptide treatment for ovarian cancer that was in Phase II
development by Angstrom. Specifically, the Company reported at that time that
the incorporation of Apricus Bio's NexACT(r) technology enabled the dose of A6 to
be cut by half, or from twice per day to once per day delivered subcutaneously,
while achieving the same level of efficacy in the mouse lung metastasis model.
Dr. Malcolm Finlayson, President and Chief Executive Officer of Angstrom,
commented, 'This study elucidates the mechanism of action and the cellular
target of the A6 peptides in blocking cancer cell migration and we believe,
when examined with the previous pre-clinical results we published in 2010 with
Apricus Bio, demonstrate that their proprietary NexACT(r) technology can play an
important role in the subcutaneous delivery of peptide drugs. We look forward
to continuing to work with Apricus Bio to develop a product or products in the
peptide field that can take advantage of NexACT(r)'s apparently positive effect
in this area.'
The abstract to the study is available and can be accessed at the following
site:
mct.aacrjournals.org/content/early/2011/08/31/1535-7163.MCT-11-0351.abstract.
About Angstrom's A6 Peptide Technology
A6 is in clinical development for ovarian cancer and in preclinical development
for the treatment of diabetic retinopathy and age-related macular degeneration.
A6 binds to the cell surface receptor CD44 and inhibits cancer cell migration.
The IC50 for A6 inhibition of chemotaxis in several human cancer cell lines is
in the nM-pM range indicating a physiologically relevant mechanism. Furthermore
the inhibition of cancer cell migration persists for 18-20 hours following the
removal of A6. A6 is stable in phosphate buffer for more than 5 years when
stored 2-8*C. A6 has been shown to have no dose-limiting toxicity in animal
studies and consistently demonstrates an excellent safety profile across animal
studies and human trials. The Company has recently completed a
placebo-controlled Phase 2 clinical trial evaluating A6 in women with
biochemical recurrent ovarian cancer. In this study, the time to tumor
progression was doubled in patients receiving A6 over that of placebo control
(p<0.01). A second Phase 2 clinical trial in patients with persistent or
recurrent ovarian cancer is in progress. This trial is being conducted by the
Gynecological Oncology Group (NCI) and the translational research component of
this study will assess CD44 as a biomarker
About Angstrom Pharmaceuticals
Angstrom Pharmaceuticals, Inc., a privately held pharmaceutical company
headquartered in San Diego, California, is developing a new class of
proprietary drugs that treat diseases involving cell migration, invasion, and
metastasis. Angstrom's lead product, A6 peptide, is a First-in-Class
'Oncoparalytic', stopping tumors from metastasizing by paralyzing cancer cells.
For further information, go to www.angstrominc.com/
Angstrom Pharmaceuticals' Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with
the exception of the historical information contained in this release, the
matters described herein contain forward-looking statements that involve risks
and uncertainties that may individually or mutually impact the matters herein
described for a variety of reasons that are outside the control of the Company.
Readers are cautioned not to place undue reliance on these forward-looking
statements as actual results could differ materially from the forward-looking
statements contained herein.
CONTACT: Angstrom Pharmaceuticals, Inc.
Dr. Malcolm Finlayson
Chief Executive Officer
990 Highland Drive, Suite 314
Solana Beach, CA 92075
Telephone: (858) 314-2356
Fax: (858) 314-2355
News Source: NASDAQ OMX
26.10.2011 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Angstrom Pharmaceuticals, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901789803
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------